← Back to guidelines
Oncology14 papers

Oligometastatic malignant neoplasm

Last edited: 4/15/2026

Overview

Oligometastatic malignant neoplasms refer to a limited number of metastatic sites, often treated with a combination of local therapy (e.g., radiotherapy) and systemic treatment to potentially extend survival without compromising quality of life 1.

Diagnosis

  • Pretreatment Workup: Comprehensive imaging (CT, MRI, PET) to identify and localize oligometastatic lesions 1.
  • Lesion Characteristics: Focus on size and number of metastatic sites, particularly relevant in lung oligometastases 1.
  • Management

  • First-Line Treatment: Systemic therapy including targeted agents and immunotherapy, tailored to primary tumor type 1.
  • Adjunctive Treatment: Local radiotherapy regimens tailored to lesion localization and size, aiming to control oligometastatic disease 1.
  • Combination Therapy: Synergistic use of radiotherapy with systemic treatments to enhance outcomes 1.
  • Special Populations

  • No Specific Guidance Provided: Abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or comorbidities 1.
  • Key Recommendations

  • Incorporate local radiotherapy for lung oligometastases in conjunction with systemic therapy to potentially prolong survival (Evidence: Moderate) 1.
  • Tailor radiotherapy regimens based on the size and location of metastatic lesions (Evidence: Expert opinion) 1.
  • Consider synergistic effects when combining radiotherapy with targeted therapies or immunotherapies (Evidence: Expert opinion) 1.
  • References

    1 Bourbonne V, Lévy A, Khalifa J, Antoni D, Blais E, Darréon J et al.. Radiotherapy in the management of lung oligometastases. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2024. link

    Original source

    1. [1]
      Radiotherapy in the management of lung oligometastases.Bourbonne V, Lévy A, Khalifa J, Antoni D, Blais E, Darréon J et al. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG